CRISPR Therapeutics AG · NASDAQ:CRSP
CRISPR Therapeutics — Corporate Update (November 2026)
40 slides from CRISPR Therapeutics's corporate update, November 2026
Slide 1: CRISPR Corporate Update
CRISPR Corporate Update Q4 Corporate Update November 2026
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation and related materials may contain statements regarding matters that are not historical facts and are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and
Slide 3: Broad Portfolio with Paradigm-Changing Approaches
Broad Portfolio with Paradigm-Changing Approaches ‘One and Done’ gene editing in Hemoglobinopathies Novel anti-coagulation pathway with siRNA Cardiovascular Disease • CTX310 (ANGPTL3) to reduce triglycerides • CTX611 siRNA targeting Factor XI for anti- and LDL-C; Phase 1b data shared at AHA 2026 coa
Slide 4: Recent Data Highlights Across the Portfolio
Recent Data Highlights Across the Portfolio • $99M CASGEVY revenue in 3Q 2026, +30% QoQ and ~6x 3Q 2025 Hemoglobinopathies • >750 patients have initiated treatment worldwide • CTX310: ~63% reduction in TG and 65% reduction in ANGPTL3 in Phase 1b sHTG study ‘One and Done' gene editing in Cardiovascul
Slide 5: Broad & Diversified Pipeline
Broad & Diversified Pipeline Program Description Disease(s) Phase of Development Partner Ex vivo CRISPR/Cas9-edited CASGEVY1 SCD and TDT Commercial autologous HSCs CTX611: FXI2 Long-acting siRNA Thromboembolic conditions Mid-stage Clinical CTX310: ANGPTL3 In vivo CRISPR/Cas9 editing sHTG, HeFH, HoFH
Slide 6: Hemoglobinopathies
Hemoglobinopathies In Vivo HSC © 2026 CRISPR Therapeutics 6
Slide 7: CASGEVY: Continued Acceleration Towards Multi-$B Potential
CASGEVY: Continued Acceleration Towards Multi-$B Potential Quarterly CASGEVY revenue since launch ($M)1 CASGEVY in the news $99M CASGEVY included in Best Inventions $76M by Time Magazine in 2024 $54M $43M $30M Consistent, strong year-over-year growth $17M $14M • $99M revenue in 3Q 2026, +30% QoQ and
Slide 8: CASGEVY: Tailwinds Support Continued Growth
CASGEVY: Tailwinds Support Continued Growth Commercial Infrastructure and Access Expanded Patient Population Investments in Manufacturing Established infrastructure and payor Expansion into pediatric population along Diversification of long-term commercial agreements providing access to advanced wit
Slide 9: Serial Innovation in Enabling Technologies To Broaden Reach
Serial Innovation in Enabling Technologies To Broaden Reach Potential to Expand the Addressable Patient Population within SCD and TDT Targeted Conditioning Antibody-drug conjugate (ADC) for specific depletion of hematopoietic stem cells (HSCs) with limited off-target or bystander toxicity TOXIN s s
Slide 10: Durable >50% HSC Editing in NHPs After a Single Dose
Durable >50% HSC Editing in NHPs After a Single Dose Validates CRISPR’s Differentiated In Vivo HSC Platform In Vivo HSC Platform is Poised for Differentiation Editing in HSCs1 following a single IV dose of LNP-mRNA Precise HSC delivery Proprietary antibody- enabling high-efficiency 60 conjugated LNP
Slide 11: 'One and Done' in Cardiovascular Diseases
‘One and Done’ in Cardiovascular Diseases CTX310 CTX340 © 2026 CRISPR Therapeutics 11
Slide 12: The Promise of 'One-and-Done' Therapies in Cardiovascular Diseases
The Promise of ‘One-and-Done’ Therapies in Cardiovascular Diseases CTX310: One-Time ANGPTL3 Editing Patients are not adherent Statin adherence in real-world registries falls below 50% at one year Single IV infusion and to ~30% by year two¹,² Removes daily adherence burden One edit, two lipids Today’
Slide 13: Transformative Data with Our First In Vivo Program – CTX310
Transformative Data with Our First In Vivo Program – CTX310 ~63% mean triglyceride reductions and ~65% mean ANGPTL3 reductions with well-tolerated safety profile in Phase 1b study for CTX310 targeting ANGPTL3 in sHTG patients Ph1b data presented at AHA in November 2026 © 2026 CRISPR Therapeutics 13
Slide 14: ANGPTL3 Associated with Low Lipids and Low CV Risk
ANGPTL3 Associated with Low Lipids and Low CV Risk Human Genetic Proof-Of-Concept Demonstrating Protective Effect of ANGPTL3 Loss-of-Function Variants Study 1: “The Long-Lived Village” Study 2: Familial Hypolipidemia • Residents of Campodimele, Italy are generally known to live • Nonsense mutations
Slide 15: CTX310: CRISPR/Cas9 Editing of ANGPTL3
CTX310: CRISPR/Cas9 Editing of ANGPTL3 Intravenous delivery CRISPR/Cas9-based editing of Reduced atherogenic targeting the liver ANGPTL3 lipoprotein concentrations CTX310 is an intravenously delivered, LNP-packaged gene editor capable of reducing ANGPTL3 expression and reducing several biomarkers as
Slide 16: CTX310 Phase 1a: Mean Percent Change in ANGPTL3 at 12 Months
CTX310 Phase 1a: Mean Percent Change from Baseline in ANGPTL3 at 12 Months Highlights Durable Editing ANGPTL3 Levels (M12) Percent change from baseline (%) • CTX310 achieved durable ANGPTL3 knock-down out to 12 -13.4% months -35.2% • Phase 1a dose escalation identified safe and effective fixed -62.8
Slide 17: CTX310 Phase 1b: ~65% ANGPTL3, ~63% TG mean reductions by D30
CTX310 Phase 1b: ~65% ANGPTL3, ~63% TG mean reductions by D30 N=10 patients with sHTG (serum TG >500 mg/dL); Participants received a one-time infusion of CTX310 at a fixed dose of 40 mg (weight <85 kg) or 50 mg (weight >85 kg)1 Mean Percent Change from Baseline in ANGPTL3 and Lipids at 30 Days (N=10
Slide 18: CTX340: A One-Time AGT Knockout for Refractory Hypertension
CTX340: A One-Time AGT Knockout for Refractory Hypertension Angiotensinogen (AGT) and hypertension Targeting AGT For Refractory Hypertension • AGT is the sole precursor of all angiotensin peptides, and CTX340 Administration Leads to Persistent Pharmacological hepatic AGT is rate-limiting for angiote
Slide 19: Novel anti-coagulation pathway with siRNA
Novel anti-coagulation pathway with siRNA CTX611 © 2026 CRISPR Therapeutics 19
Slide 20: CTX611 is a Factor XI siRNA that aims to minimize bleeding risk
CTX611 is a Factor XI siRNA that aims to minimize bleeding risk by preserving hemostatic clotting Current anti-coagulation drugs fail to address unmet needs Factor XI disrupts thrombosis while maintaining hemostatic clotting • Factor Xa and thrombin inhibitors block both pathological and hemostatic
Slide 21: CTX611 Phase 1 Data: Deep, Durable Reductions in FXI Activity
CTX611 Phase 1 Data: Shows Deep, Durable Reductions in FXI Activity CTX611 Phase I Clinical Results: Dose-dependent pharmacodynamic response to therapy sustained through Month 6 FXI Antigen (n = 32 subjects; 8 each arm) FXI Activity (n = 32 subjects; 8 each arm) 95.0% peak reduction in FXI antigen 9
Slide 22: Best-In-Class Potential Supported by Phase I Clinical Data
Best-In-Class Potential Supported by Phase I Clinical Data CTX611 (siRNA)1 Antibody Small Molecule Company CRISPR Novartis / Anthos BMS / J&J Bayer Drug candidate CTX611 Abelacimab Milvexian Asundexian Current clinical stage Phase 2 Phase 3 Phase 3 Phase 3 Route of administration SC SC / IV Oral Ora
Slide 23: CTX611 Phase II Trials: TKA Top-Line Data Expected in 2H
CTX611 Phase II Trials: TKA Top-Line Data Expected in 2H 2026 CTX611-201 Phase II TKA Study Design CTX611-202 Phase II CV Study Design Objective: Establish PoC efficacy in TKA-VTE participant population Objective: Establish PK-PD in chronic “arterial” population; evaluate PD profile of CTX611 with A
Slide 24: Major Opportunity in Secondary Stroke Prevention Market
Major Opportunity in Secondary Stroke Prevention (SSP) Market driven by Clinical De-Risking and Compounding Patient Population CTX611 Commercial Opportunity is Driven by High Annual Incidence and Long- Clinical Derisking for FXI in Large Ph3 SSP Trials term Adherence to Prevent Stroke Recurrence ANN
Slide 25: CTX611 Has Significant Potential Across Multiple Indications
CTX611 Has Significant Potential Across Multiple Indications US Potential Market Opportunity for FXI Anticoagulation Agent ~10.5M Number of Patients ~2M ~800K ~300K ~250K ~100K Atrial Fibrillation Atrial Fibrillation Secondary Stroke PAD Post ESRD Patients Cancer (all diagnosed)¹ (DOAC Ineligible) P
Slide 26: 'Immune Reset' using CAR-T
‘Immune Reset’ using CAR-T Zugo-cel In Vivo CAR-T © 2026 CRISPR Therapeutics 26
Slide 27: CAR-Ts Offer the Possibility of Immune Reset
CAR-Ts Offer the Possibility of Immune Reset to Reach Long Term Drug-Free Remission for Autoimmune Diseases (AID) Zugo-cel is an allogenic CAR T with several CAR-T aims to clear autoreactive B-cells and AutoCAR-T is showing early promise in novel potency edits reestablish naïve population clinical s
Slide 28: Zugo-cel Development Across Autoimmune Disease and Oncology
Zugo-cel Development Across Autoimmune Disease and Oncology Autoimmune Disease Immuno-Oncology Three Phase 1 basket trials Phase 1/2 trial in relapsed or refractory B-cell malignancies Rheumatology Large B-cell lymphoma 1 Data at ACR 2026 1 Data at ASH 2026 SLE · Systemic sclerosis · IIM DLBCL NOS ·
Slide 29: Zugo-cel in AID: Convenient Dosing with Several Advantages
Zugo-cel in AID: Convenient Dosing with Several Advantages Allogeneic CAR-T – convenient dosing paradigm and follow-up in clinical trial Primary assessment and Off-the-shelf product Lymphodepletion Single Zugo-cel infusion follow-up Available on site: Fludarabine 30 mg/m² + cyclophos 500 Dose escala
Slide 30: Zugo-cel Expansion and B-Cell Kinetics Across SSc, IIM, and SLE
Zugo-cel Expansion and B-Cell Kinetics Across SSc, IIM, and SLE N=13 cumulative patients dosed across SSc, IIM, and SLE in Phase 1 trial Autoimmune indications (SSc, Myositis, SLE) ZUGO-CEL EXPANSION B-CELL KINETICS CAR⁺ T cells / µg vs. days since infusion B cells / µL vs. days since infusion • Mea
Slide 31: Single Zugo-cel Infusion Led to 5/6 rCRISS-25 at Month 3
Single Zugo-cel Infusion Led to 5/6 rCRISS-25 at Month 3 Patient demographics Clinical Efficacy 5/6 rCRISS-25 at M3 with standard LD; durable rCRISS-50 at M6 Data cut off date: July, 2026 Eligibility: adults with dcSSc (2013 ACR/EULAR criteria), <7 years from first non-Raynaud's symptom, with active
Slide 32: Case Studies of IIM and SLE Patients Treated with Zugo-cel
Case Studies of IIM (n=1) and SLE Patients (n=2) Treated with Zugo-cel Case Study of an IIM Participant with Zugo-cel Case Study of SLE Patients treated with Zugo-cel Clinical Efficacy Results at DL1 (100M cells) Clinical Efficacy Results at DL1 (100M cells) IIM-1 DORIS Clinical Remission DORIS Clin
Slide 33: Zugo-cel Immuno-Oncology Trial: Design and Baseline Characteristics
Zugo-cel Immuno-Oncology Trial: Design and Baseline Characteristics Open-label, multicenter Phase 1/2 study in R/R B-cell malignancies; baseline shown for LBCL at DL4 (N = 10) Phase 1/2 Trial Design Baseline Characteristics (LBCL, DL4, N = 10) Baseline characteristic Total N = 10 Population: adults
Slide 34: Zugo-cel Ph1 Data Suggest Durability in LBCL at RP2D
Zugo-cel Ph1 Data Suggest Durability in LBCL at RP2D (600M) (N=10 with D28 response assessment1) CR PR PD LBCL Pt 1 Second zugo-cel infusion LBCL Pt 2 Response assessment LBCL Pt 3 LBCL Pt 4 LBCL Pt 5 • ORR 90%, CRR 70% at DL4 (600M LBCL Pt 6 cell dose) LBCL Pt 7 • 2 CRs ongoing at 12-mo visit • 83%
Slide 35: DuraCAR-T: CRISPR's In Vivo Transient CAR-T Platform
DuraCAR-T: CRISPR’s In Vivo Transient CAR-T Platform DuraCAR-T: Best-in-Class In Vivo CAR-T Extended Durability Targeted Delivery Proprietary Binders Dosing Flexibility Optimized mRNA formats for Re-dosable LNP formulation T cell specific delivery with CD8 binders prioritized for longer protein half
Slide 36: DuraCAR-T Induced Robust B Cell Depletion at Low Doses
DuraCAR-T Induced Robust B Cell Depletion in the Blood, Bone Marrow, Spleen, and Lymph Node at low doses of 0.25 mg/kg Blood Bone Marrow Spleen Lymph Node (Day 8) (Day 10 or 14*) (Day 5, 8, 10) 1.5×10 6 0.5mg/kg * 2 0.25mg/kg * 3 (CD20+ B Cells) 1×10 6 0.5mg/kg * 2 100 100 100 Cells/mL % B Cell Depl
Slide 37: Potentially Curative Therapies for Rare Diseases
Potentially Curative Therapies for Rare Diseases CTX460 CTX213 © 2026 CRISPR Therapeutics 37
Slide 38: CTX460: Proprietary SyNTase Editing for Alpha-1 Antitrypsin Deficiency
CTX460: Proprietary SyNTase Editing to Develop a Best-in-Class Treatment for Alpha-1 Antitrypsin Deficiency SyNTase Editor: Synthetic Nucleotide Template Polymerase CTX460 Targeting SERPINA1 for AATD • Alpha-1 antitrypsin deficiency (AATD) is caused by mutations in the Engineered synthetic SERPINA1
Slide 39: CTX213: Deviceless Hypoimmune Islet Cell Therapy for T1D
CTX213: Deviceless Hypoimmune Islet Cell Therapy for T1D CTX211, a gene-edited, stem cell–derived encapsulated cell CTX213, an unencapsulated iPSC-derived islet cell product product for the treatment of type 1 diabetes utilizing the same edits as CTX211 • Ph1 completed in n=5 patients • Well-tolerat
Slide 40: © 2026 CRISPR Therapeutics
© 2026 CRISPR Therapeutics 40
CRISPR Therapeutics — Corporate Update (November 2026) on 6ix